skip to main content

Clostridioides difficile Infection — Medical Practice MCQ

Instant feedback + full explanation. One question, done properly.

HardInfectious DiseasesClostridioides difficile Infection

A kidney-transplant recipient has rising CMV DNA despite exposure-appropriate valganciclovir and then foscarnet; adherence and absorption are confirmed, and renal toxicity now limits foscarnet. Which NICE-recommended option is specifically relevant?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: B — Maribavir within its authorisation for refractory post-transplant CMV

B is correct. NICE TA860 recommends maribavir for adult solid-organ or stem-cell transplant recipients with CMV refractory to standard agents including ganciclovir, valganciclovir, cidofovir or foscarnet. A is principally prophylactic, not the established salvage treatment here. C lacks adequate CMV activity. D invents an antiviral combination and unsafe graft plan. E is not effective stand-alone therapy.

Reference: NICE TA860: maribavir for refractory CMV after transplant: https://www.nice.org.uk/guidance/ta860/chapter/1-Recommendations